Whole-cell immune system interaction

Whole-cell immune system interaction is a descriptive category used in pharmacology to denote instances where a drug or compound modulates immune activity through mechanisms that are not yet mapped to a specific molecular target (Moffat et al., 2017). This classification is common in phenotypic drug discovery, where compounds are selected based on their ability to produce a desired effect in complex cellular environments, such as inhibiting T-cell activation or altering cytokine profiles (Terstappen et al., 2007). While this approach can identify novel therapeutic pathways, the lack of a defined molecular target presents significant challenges for lead optimization and safety profiling (Haasen et al., 2017). Historically, many important immunomodulators were discovered this way, with their specific targets—such as receptors or intracellular enzymes—only being identified years after clinical use (Swinney & Anthony, 2011). Consequently, this entry serves as a placeholder until target deconvolution studies can elucidate the exact molecular site of action (Ziegler et al., 2013).

Other names

Phenotypic immune interactionUnspecified immune system modulationCell-based immune responseNon-specific immune activation

The mechanism of action is undefined at the molecular level; biological activity is characterized by functional changes in immune cell populations or systemic inflammatory markers rather than binding to a specific protein (Moffat et al., 2017; Terstappen et al., 2007).